Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
BACKGROUND
Targeting CTLA-4 is a recent strategic approach in cancer control: blocking CTLA-4 enhances an antitumor immunity by promoting T-cell activation and cytotoxic T-lymphocyte proliferation. This induction of a tolerance break against the tumor may be responsible for immune-related adverse events (irAEs). Our objective was to assess the incidence and nature of irAEs in oncologic patients receiving anti-CTLA-4 antibodies (ipilimumab and tremelimumab).


METHODS
A systematic search of literature up to February 2014 was performed in MEDLINE, EMBASE, and Cochrane databases to identify relevant articles. Paired reviewers independently selected articles for inclusion and extracted data. Pooled incidence was calculated using R(©), package meta.


RESULTS
Overall, 81 articles were included in the study, with a total of 1265 patients from 22 clinical trials included in the meta-analysis. Described irAEs consisted of skin lesions (rash, pruritus, and vitiligo), colitis, and less frequently hepatitis, hypophysitis, thyroiditis, and some rare events such as sarcoidosis, uveitis, Guillain-Barré syndrome, immune-mediated cytopenia and polymyalgia rheumatic/Horton. The overall incidence of all-grade irAEs was 72 % (95 % CI, 65-79 %). The overall incidence of high-grade irAEs was 24 % (95 % CI, 18-30 %). The risk of developing irAEs was dependent of dosage, with incidence of all-grade irAEs being evaluated to 61 % (95 % CI, 56-66 %) for ipilimumab 3 mg/kg and 79 % (95 % CI, 69-89 %) for ipilimumab 10 mg/kg. Death due to irAEs occurred in 0.86 % of patients. The median time of onset of irAEs was about 10 weeks (IQR, 6-12) after the onset of treatment, corresponding with the first three cycles but varied according to the organ system involved. Such immune activation could also be indicative for tumor-specific T-cell activation and irAE occurrence was associated with clinical response to CTLA-4 blocking in 60 % of patients.


CONCLUSIONS
The price of potential long-term survival to metastatic tumors is an atypical immune toxicity, reflecting the mechanism of action of anti-CTLA-4 antibodies. A better knowledge of these irAEs and its management in a multidisciplinary approach will help to reduce morbidity and therapy interruptions.
Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. anne.bertrand87@gmail.com.
Anne
A
Bertrand
Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. mariekostine@hotmail.fr.
Marie
M
Kostine
Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. thomas.barnetche@chu-bordeaux.fr.
Thomas
T
Barnetche
Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. marie-elise.truchetet@chu-bordeaux.fr.|Laboratoire d'Immunologie, UMR-CNRS 5164, Université de Bordeaux, Bordeaux, France. marie-elise.truchetet@chu-bordeaux.fr.
Marie-Elise
ME
Truchetet
Département de Rhumatologie, Hôpital Pellegrin, CHU de Bordeaux, Bordeaux, France. thierry.schaeverbeke@chu-bordeaux.fr.|Unité sous Contrat, Infections à Mycoplasmes et à Chlamydia chez l'Homme, Université de Bordeaux, Bordeaux, France. thierry.schaeverbeke@chu-bordeaux.fr.
Thierry
T
Schaeverbeke
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D060908:CTLA-4 Antigen / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D007167:Immunotherapy / Q000009:adverse effects; D000074324:Ipilimumab; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007155:Immunologic Factors; D000074324:Ipilimumab; C520704:tremelimumab